GlobeNewswire·Aug 6, 2026, 8:30 AM ET

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

RNXT

RenovoRx, Inc. (NASDAQ: RNXT) announced the first commercial clinical use of its RenovoCath device for treating a sarcoma patient at the CARTI Cancer Center Little Rock.
Treatment began in late June 2026 and remains ongoing, utilizing the device to deliver chemotherapy locally near the tumor rather than via systemic intravenous administration.
CARTI is concurrently using RenovoCath for localized drug delivery in pancreatic cancer cases, demonstrating the technology's expanding application across different tumor types.
Dr. Edgar St. Amour of CARTI noted that sarcoma is often challenging to treat with systemic chemotherapy due to diverse locations, while local delivery via RenovoCath may reduce toxicity.
Ramtin Agah, MD, Chief Medical Officer of RenovoRx, stated this milestone highlights RenovoCath's potential as a stand-alone device for solid tumors beyond its core focus on pancreatic adenocarcinoma.
RenovoCath is FDA-cleared for isolating blood flow, delivering fluids, & temporary vessel occlusion for applications such as arteriography, preoperative occlusion, & chemotherapeutic infusion.
In 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales, with a record $563,000 in sales recorded during the first quarter of 2026.
The company is evaluating its drug-device combination candidate, intra-arterial gemcitabine delivered via RenovoCath (IAG), in the Phase III TIGeR-PaC trial.
RenovoRx anticipates full enrollment in the TIGeR-PaC trial in the near term, with a final data readout expected in mid to late 2027.
IAG has received Orphan Drug Designation for pancreatic cancer & bile duct cancer, granting seven years of market exclusivity upon FDA approval.
RenovoRx is actively working to expand orders from medical institutions, including National Cancer Institute-designated centers.